Clinical Trials Browser

OTHER × Cytokine Release Syndrome × Plasma cell × Clear all

NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2 Completed

24 enrolled 8 charts

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06421675 2026-04-27

EMBRACE

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Phase 2 Withdrawn

Cytokine Release Syndrome, Multiple Myeloma

NCT05414162 2022-06-15

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Follicular, Multiple Myeloma, Myocarditis